Silo Pharma Announces Pricing of $2 Million Public Offering
Silo Pharma (NASDAQ: SILO) has announced the pricing of a $2 million public offering consisting of 3,333,338 shares of common stock (or pre-funded warrants) along with Series A-1 and A-2 warrants. The offering is priced at $0.60 per share with associated warrants. Both Series A-1 and A-2 warrants have an exercise price of $0.60, with A-1 warrants expiring in 5 years and A-2 warrants in 18 months.
H.C. Wainwright & Co. is serving as the exclusive placement agent. The offering is expected to close around May 16, 2025. The company plans to use the net proceeds for general working capital purposes. The offering is made through an effective SEC registration statement on Form S-1.
Silo Pharma (NASDAQ: SILO) ha annunciato il prezzo di un offerta pubblica da 2 milioni di dollari composta da 3.333.338 azioni ordinarie (o warrant pre-finanziati) insieme ai warrant Serie A-1 e A-2. L'offerta è stata fissata a 0,60 dollari per azione con i warrant associati. Entrambi i warrant Serie A-1 e A-2 hanno un prezzo di esercizio di 0,60 dollari, con i warrant A-1 che scadono dopo 5 anni e i warrant A-2 dopo 18 mesi.
H.C. Wainwright & Co. agisce come agente di collocamento esclusivo. La chiusura dell'offerta è prevista intorno al 16 maggio 2025. La società intende utilizzare i proventi netti per scopi generali di capitale circolante. L'offerta viene effettuata tramite una dichiarazione di registrazione efficace presso la SEC sul modulo S-1.
Silo Pharma (NASDAQ: SILO) ha anunciado el precio de una oferta pública de 2 millones de dólares que consiste en 3,333,338 acciones ordinarias (o warrants prefinanciados) junto con warrants Serie A-1 y A-2. La oferta tiene un precio de 0,60 dólares por acción con warrants asociados. Tanto los warrants Serie A-1 como A-2 tienen un precio de ejercicio de 0,60 dólares, con los warrants A-1 que vencen en 5 años y los A-2 en 18 meses.
H.C. Wainwright & Co. actúa como agente de colocación exclusivo. Se espera que la oferta se cierre alrededor del 16 de mayo de 2025. La compañía planea usar los ingresos netos para propósitos generales de capital de trabajo. La oferta se realiza a través de una declaración de registro efectiva ante la SEC en el formulario S-1.
Silo Pharma (NASDAQ: SILO)가 200만 달러 규모의 공개 모집 가격을 발표했습니다. 이번 공개 모집은 보통주 3,333,338주(또는 선출자격 워런트)와 시리즈 A-1 및 A-2 워런트로 구성되어 있습니다. 주당 가격은 0.60달러이며, 이에 따른 워런트가 포함됩니다. 시리즈 A-1과 A-2 워런트 모두 행사 가격이 0.60달러이며, A-1 워런트는 5년 후 만료되고 A-2 워런트는 18개월 후 만료됩니다.
H.C. Wainwright & Co.가 단독 배정 대행사로 활동합니다. 이번 공개 모집은 2025년 5월 16일경 마감될 예정입니다. 회사는 순수익을 일반 운전자본 용도로 사용할 계획입니다. 이 공개 모집은 SEC의 S-1 양식에 따른 유효 등록 신고서를 통해 진행됩니다.
Silo Pharma (NASDAQ : SILO) a annoncé le prix d'une offre publique de 2 millions de dollars comprenant 3 333 338 actions ordinaires (ou bons de souscription préfinancés) ainsi que des bons de souscription de séries A-1 et A-2. L'offre est fixée à 0,60 dollar par action avec des bons associés. Les bons de souscription des séries A-1 et A-2 ont tous deux un prix d'exercice de 0,60 dollar, les bons A-1 expirant dans 5 ans et les A-2 dans 18 mois.
H.C. Wainwright & Co. agit en tant qu'agent de placement exclusif. La clôture de l'offre est prévue autour du 16 mai 2025. La société prévoit d'utiliser le produit net à des fins générales de fonds de roulement. L'offre est réalisée via une déclaration d'enregistrement effective auprès de la SEC sur le formulaire S-1.
Silo Pharma (NASDAQ: SILO) hat die Preisfestsetzung für ein öffentliches Angebot in Höhe von 2 Millionen US-Dollar bekannt gegeben, das aus 3.333.338 Stammaktien (oder vorfinanzierten Warrants) sowie Series A-1 und A-2 Warrants besteht. Das Angebot ist mit 0,60 US-Dollar pro Aktie inklusive zugehöriger Warrants bewertet. Sowohl die Series A-1 als auch die A-2 Warrants haben einen Ausübungspreis von 0,60 US-Dollar, wobei die A-1 Warrants in 5 Jahren und die A-2 Warrants in 18 Monaten verfallen.
H.C. Wainwright & Co. fungiert als exklusiver Platzierungsagent. Der Abschluss des Angebots wird für den 16. Mai 2025 erwartet. Das Unternehmen plant, die Nettoerlöse für allgemeine Betriebskapitalzwecke zu verwenden. Das Angebot erfolgt über eine wirksame SEC-Registrierungserklärung auf Formular S-1.
- Access to $2 million in additional capital for working capital purposes
- Successfully secured institutional placement agent H.C. Wainwright & Co.
- Potential significant dilution for existing shareholders due to new share issuance
- Additional dilution risk from warrant exercises at $0.60 per share
- Low offering price indicating potential market weakness
Insights
Silo Pharma's $2M offering at $0.60/share with equal warrant coverage indicates significant dilution and financing challenges despite providing short-term operational runway.
Silo Pharma's $2 million public offering reveals concerning financial positioning for this developmental-stage biopharmaceutical company. The offering is structured at
The structure of this financing - specifically the inclusion of both long and short-term warrants with exercise prices equal to the offering price - suggests challenging capital-raising conditions. Typically, warrants are offered at a premium to the current stock price, so this at-the-money exercise price indicates investors required substantial incentives to participate. The dual-warrant structure effectively gives investors multiple opportunities to acquire shares at today's price even if the stock appreciates.
The stated use of proceeds for "general working capital purposes" rather than specific R&D milestones is particularly troubling for a developmental biotech. This suggests the capital raise is primarily addressing immediate operational needs rather than advancing clinical programs. Without specified allocation toward pipeline advancement, this appears to be primarily a survival-focused financing.
H.C. Wainwright's involvement as placement agent also points to a challenging raise, as smaller investment banks typically handle offerings for microcap companies facing difficulties attracting institutional investment. After fees, the net proceeds will be meaningfully less than the
SARASOTA, FL, May 15, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the pricing of a public offering of 3,333,338 shares of common stock (or pre-funded warrants in lieu thereof), together with series A-1 warrants (“Series A-1 Warrants”) to purchase up to 3,333,338 shares of common stock and series A-2 warrants (“Series A-2 Warrants”) to purchase up to 3,333,338 shares of common stock at a combined public offering price of
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
The gross proceeds to the Company from the offering are expected to be approximately
A registration statement on Form S-1 (File No. 333-286777) relating to the securities described above has been filed with the Securities and Exchange Commission, or the SEC, and was declared effective by the SEC on May 15, 2025. The offering will be made only by means of a prospectus, which is part of the effective registration statement. A preliminary prospectus relating to the offering has been filed with the SEC. When available, electronic copies of the final prospectus may be obtained for free on the SEC’s website located at http://www.sec.gov and may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About Silo Pharma
Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company focused on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories. silopharma.com
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including statements pertaining to the completion of the offering, the satisfaction of customary closing conditions related to the offering, the intended use of proceeds from the offering, changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factor. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events, or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.
Contact
800-705-0120
investors@silopharma.com
FAQ
What is the size and price of Silo Pharma's (SILO) May 2025 public offering?
How will Silo Pharma (SILO) use the proceeds from its $2M offering?
What are the terms of the warrants in Silo Pharma's May 2025 offering?
Who is the placement agent for Silo Pharma's (SILO) May 2025 offering?
When is Silo Pharma's (SILO) public offering expected to close?
